Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chroni Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15407. [Epub ahead of print]

PMID:
29808926
2.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research.

Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.

3.

HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.

Ducreux S, Dubois V, Amokrane K, Yakoub-Agha I, Labalette M, Michallet M, Rubio MT, Kennel A, Forcade E, Lafarge X, Bulabois CE, Masson D, Daguindau E, Devys A, Moalic V, Quelvennec E, Boudifa A, Picard C, Van Endert P, de Matteis M, Delbos F, Filloux M, Pedron B, Renac V, Hau F, Bonneau J, Parissiadis A, Fort M, Dormoy A, Maillard N, Jollet I, Chevallier P, Cesbron A, Bay JO, Quainon F, Garnier F, Socié G, Loiseau P, Porcher R, Peffault de Latour R; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC); Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. [Epub ahead of print]

PMID:
29726580
4.

Alemtuzumab versus anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.

Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ.

Eur J Haematol. 2018 Apr 30. doi: 10.1111/ejh.13085. [Epub ahead of print]

PMID:
29714032
5.
6.

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.

Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socié G, Tabrizi R, Cornelissen JJ, Ghavamzadeh A, Huynh A, Wu D, Yakoub-Agha I, Maertens J, Chevallier P, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Apr 16. doi: 10.1038/s41409-018-0169-6. [Epub ahead of print]

PMID:
29662244
7.

Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study.

Alsuliman T, Kitel C, Dulery R, Guillaume T, Larosa F, Cornillon J, Labussière-Wallet H, Médiavilla C, Belaiche S, Delage J, Alain S, Yakoub-Agha I.

Bone Marrow Transplant. 2018 Apr 13. doi: 10.1038/s41409-018-0166-9. [Epub ahead of print]

PMID:
29654288
8.

Late effects after hematopoietic stem cell transplantation for beta-thalassemia major: the French national experience.

Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, Pondarré C, Dalle JH, Peffault de Latour R, Michallet M, Steschenko D, Moshous D, Lutz P, Stephan JL, Rohrlich PS, Yakoub-Agha I, Bernaudin F, Piguet C, Aladjidi N, Badens C, Berger C, Socié G, Dumesnil C, Castex MP, Poirée M, Lambilliotte A, Thomas C, Simon P, Auquier P, Michel G, Loundou A, Agouti I, Thuret I.

Haematologica. 2018 Mar 29. pii: haematol.2017.183467. doi: 10.3324/haematol.2017.183467. [Epub ahead of print]

9.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):778-785. doi: 10.1002/ajh.25091. Epub 2018 Mar 30.

PMID:
29574915
10.

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.

Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, Mohty M, Yakoub-Agha I, Bay JO, Perrot A, Bulabois CE, Huynh A, Mercier M, Frenzel L, Avet-Loiseau H, de Latour RP, Cornillon J.

Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print]

PMID:
29523884
11.

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G.

Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.

PMID:
29473209
12.

Successful treatment with fingolimod of graft-versus-host disease of the central nervous system.

Gauthier J, Vermersch P, Chauvet P, Varlet P, Coiteux V, Magro L, Yakoub-Agha I.

Blood Adv. 2018 Jan 2;2(1):10-13. doi: 10.1182/bloodadvances.2017011478. eCollection 2018 Jan 9.

13.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N.

Biol Blood Marrow Transplant. 2018 May;24(5):930-936. doi: 10.1016/j.bbmt.2018.01.006. Epub 2018 Jan 12.

PMID:
29339268
14.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 May;53(5):617-624. doi: 10.1038/s41409-017-0067-3. Epub 2018 Jan 15.

PMID:
29335632
15.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, Nguyen S, Forcade E, Régny C, Bay JO, Bazarbachi A, Rohrlich PS, Huynh A, Farhi J, Marchand T, Malfuson JV, Pilorge S, Labussière-Wallet H, Renard C, Fornecker LM, Detrait M, Duléry R, Delage J, Ménard AL, Charbonnier A, Nelken B, Jubert C, Suarez F, de la Tour RP, Beguin Y, Schoemans H, Blaise D, Yakoub-Agha I.

Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.

PMID:
29330405
16.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A.

Blood Adv. 2017 Feb 28;1(7):477-485. doi: 10.1182/bloodadvances.2016002386. eCollection 2017 Feb 28.

17.

Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party.

Paviglianiti A, Dalle JH, Ayas M, Boelens JJ, Volt F, Iori AP, de Souza MP, Diaz MA, Michel G, Locatelli F, Jubert C, Yakoub-Agha I, Bittencourt H, Bertrand Y, Kenzey C, Tozatto Maio K, Hayashi H, Rocha V, Bader P, Gluckman E, Ruggeri A.

Biol Blood Marrow Transplant. 2018 Apr;24(4):799-805. doi: 10.1016/j.bbmt.2017.12.790. Epub 2017 Dec 27.

PMID:
29288817
18.

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

Vallet N, de Fontbrune FS, Loschi M, Desmier D, Villate A, Barraco F, Chevallier P, Terriou L, Yakoub-Agha I, Ruggeri A, Mohty M, Maillard N, Rohrlich PS, Ceballos P, Nguyen S, Poiré X, Guillerm G, Tabrizi R, Farhi J, Devillier R, Rubio MT, Socié G, de Latour RP; Société Francophone de Greffe de Moelle et Thérapie Cellulaire.

Haematologica. 2018 Mar;103(3):e103-e105. doi: 10.3324/haematol.2017.182360. Epub 2017 Dec 21. No abstract available.

19.

Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.

Hueso T, Gauthier J, Joncquel Chevalier-Curt M, Magro L, Coiteux V, Dulery R, Carpentier B, Labreuche J, Damaj G, Yakoub-Agha I, Seguy D.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):908-917.e2. doi: 10.1016/j.cgh.2017.12.024. Epub 2017 Dec 16.

PMID:
29258901
20.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

PMID:
29226497
21.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

22.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

PMID:
29196078
23.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É, Dumesnil C, Guillaume T, Huynh A, Levrat SM, Menard AL, Michallet M, Pautas C, Poiré X, Ravinet A, Yakoub-Agha I, Bazarbachi A.

Bull Cancer. 2017 Dec;104(12S):S84-S98. doi: 10.1016/j.bulcan.2017.05.009. Epub 2017 Nov 26. Review. French.

PMID:
29179894
24.

[Management of the chronic graft versus host disease: Guidelines from the Francophone society of bone marrow transplantation and cellular therapies (SFGM-TC)].

Magro L, Forcade E, Giraud C, Granata A, Parquet N, Rohrlich PS, Terriou L, Yakoub-Agha I, Beguin Y.

Bull Cancer. 2017 Dec;104(12S):S145-S168. doi: 10.1016/j.bulcan.2017.10.023. Epub 2017 Nov 24. Review. French.

PMID:
29174321
25.

[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Yakoub-Agha I, Ferrand C, Chalandon Y, Ballot C, Castilla Llorente C, Deschamps M, Gauthier J, Labalette M, Larghero J, Maheux C, Moreau AS, Varlet P, Pétillon MO, Pinturaud M, Rubio MT, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S43-S58. doi: 10.1016/j.bulcan.2017.10.017. Epub 2017 Nov 23. French.

PMID:
29174320
26.

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J.

Bull Cancer. 2017 Dec;104(12S):S131-S135. doi: 10.1016/j.bulcan.2017.10.018. Epub 2017 Nov 22. Review. French.

PMID:
29173980
27.

[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y.

Bull Cancer. 2017 Dec;104(12S):S99-S105. doi: 10.1016/j.bulcan.2017.07.010. Epub 2017 Nov 23. Review. French.

PMID:
29173979
28.

[Allogeneic hematopoietic cell transplantation for Hodgkin's disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J.

Bull Cancer. 2017 Dec;104(12S):S112-S120. doi: 10.1016/j.bulcan.2017.06.020. Epub 2017 Nov 23. French.

PMID:
29173978
29.

[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Boiron JM, Garban F, Audat F, Ader V, Andreu H, Aubrège-Bouvier C, Borel C, Huynh P, Nacimento F, Yakoub-Agha I, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S76-S83. doi: 10.1016/j.bulcan.2017.06.022. Epub 2017 Nov 22. French.

PMID:
29173975
30.

[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Pugnet G, Castilla-Llorente C, Puyade M, Terriou L, Badoglio M, Deligny C, Guillaume-Jugnot P, Labeyrie C, Benzidia I, Faivre H, Lansiaux P, Marjanovic Z, Bourhis JH, Faucher C, Furst S, Huynh A, Martin T, Vermersch P, Yakoub-Agha I, Farge D.

Bull Cancer. 2017 Dec;104(12S):S169-S180. doi: 10.1016/j.bulcan.2017.06.019. Epub 2017 Nov 22. Review. French.

PMID:
29173974
31.

[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J.

Bull Cancer. 2017 Dec;104(12S):S121-S130. doi: 10.1016/j.bulcan.2017.05.010. Epub 2017 Nov 22. Review. French.

PMID:
29173973
32.

[How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)].

Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S.

Bull Cancer. 2017 Dec;104(12S):S181-S187. doi: 10.1016/j.bulcan.2017.10.022. Epub 2017 Nov 21. Review. French.

PMID:
29169653
33.

[Preservation/congelation of hematopoietic stem cell grafts in a pediatric context: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

De Vos J, de Berranger E, Jubert C, Pochon C, Letellier C, Mialou V, Sirvent A, Yakoub-Agha I, Dalle JH.

Bull Cancer. 2017 Dec;104(12S):S136-S141. doi: 10.1016/j.bulcan.2017.04.008. Epub 2017 Nov 21. Review. French.

PMID:
29169651
34.

[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J.

Bull Cancer. 2017 Dec;104(12S):S106-S111. doi: 10.1016/j.bulcan.2017.08.008. Epub 2017 Nov 21. Review. French.

PMID:
29169650
35.

[HLA coding in ProMISe: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Raus N, Faucher C, Kennel A, Pereira M, Veron C, Yakoub-Agha I, Loiseau P.

Bull Cancer. 2017 Dec;104(12S):S65-S70. doi: 10.1016/j.bulcan.2017.06.021. Epub 2017 Nov 8. Review. French.

PMID:
29128085
36.

[Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Dubois V, Alizadeh M, Bourhis JH, Etancelin P, Farchi O, Ferrand C, Goursaud L, Mollet I, Renac V, Varlet P, Yakoub-Agha I, Bay JO.

Bull Cancer. 2017 Dec;104(12S):S59-S64. doi: 10.1016/j.bulcan.2017.08.010. Epub 2017 Nov 8. French.

PMID:
29128084
37.

[National care logbook for patients undergoing autologous hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Porcheron S, Balcaen S, Cardinael N, Courbon C, Dendoncker C, Faivre-Lescat H, François G, Gilis L, Guiraud M, Schmitt S, Vercasson M, Adam C, Yakoub-Agha I.

Bull Cancer. 2017 Dec;104(12S):S142-S144. doi: 10.1016/j.bulcan.2017.09.016. Epub 2017 Nov 8. French.

PMID:
29128082
38.

[Information booklet for related hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Polomeni A, Tardieu L, Ainaoui M, Andrianne C, Bancillon N, Chapel V, Chevallier N, Evrard S, Fournier I, Gargallo G, Godin S, Issarni D, Le Bars L, Renaud B, Yakoub-Agha I, Wallart A, De Bentzmann N.

Bull Cancer. 2017 Dec;104(12S):S71-S75. doi: 10.1016/j.bulcan.2017.08.009. Epub 2017 Nov 8. French.

PMID:
29126585
39.

How to build an allogeneic hematopoietic cell transplant unit in 2016: Proposal for a practical framework.

Crysandt M, Yakoub-Agha I, Reiß P, Theisen S, Silling G, Glatte P, Nelles E, Lemmen S, Brümmendorf TH, Kontny U, Jost E.

Curr Res Transl Med. 2017 Nov;65(4):149-154. doi: 10.1016/j.retram.2017.10.003. Epub 2017 Nov 6.

PMID:
29122584
40.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3.

41.

Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT.

Gonzales F, Bruno B, Alarcón Fuentes M, De Berranger E, Guimber D, Behal H, Gandemer V, Spiegel A, Sirvent A, Yakoub-Agha I, Nelken B, Duhamel A, Seguy D.

Clin Nutr. 2017 Oct 12. pii: S0261-5614(17)31365-1. doi: 10.1016/j.clnu.2017.10.005. [Epub ahead of print]

PMID:
29097037
42.

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.

Gauthier J, Yakoub-Agha I.

Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Review.

PMID:
28988742
43.

Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).

Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, Schaap N, Cornelissen JJ, Maillard N, Pioltelli P, Gedde-Dahl T, Lenhoff S, Houhou M, Esteve J, Mohty M, Nagler A.

Am J Hematol. 2018 Jan;93(1):31-39. doi: 10.1002/ajh.24928. Epub 2017 Oct 31.

PMID:
28971504
44.

Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.

Gorin NC, Labopin M, Pabst T, Remenyi P, Wu D, Huynh A, Volin L, Cahn JY, Yakoub-Agha I, Mercier M, Houhou M, Mohty M, Nagler A; Acute Leukemia Working Party of the EBMT.

Am J Hematol. 2017 Dec;92(12):1318-1323. doi: 10.1002/ajh.24904. Epub 2017 Sep 28.

PMID:
28960419
45.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
46.

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.

Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, Tabrizi R, Magro L, Vanhove B, Blancho G, Moreau P, Gaugler B, Chevallier P, Mohty M.

Blood. 2017 Nov 16;130(20):2186-2195. doi: 10.1182/blood-2017-05-786137. Epub 2017 Sep 1.

PMID:
28864814
47.

Soluble Interleukin-7 receptor levels and risk of acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

Kielsen K, Shamim Z, Thiant S, Faucher S, Decker W, Christensen IJ, Ryder LP, Yakoub-Agha I, Müller K.

Clin Immunol. 2018 Feb;187:26-32. doi: 10.1016/j.clim.2017.08.015. Epub 2017 Aug 31.

PMID:
28863969
48.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.

PMID:
28846465
49.

Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes.

Bonnet S, Duléry R, Regany K, Bouketouche M, Magro L, Coiteux V, Alfandari S, Berthon C, Quesnel B, Yakoub-Agha I.

Curr Res Transl Med. 2017 Apr - Jun;65(2):77-81. doi: 10.1016/j.retram.2017.05.003. Epub 2017 Jul 5.

PMID:
28689016
50.

Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.

Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V.

Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26.

PMID:
28650455

Supplemental Content

Loading ...
Support Center